Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023.
- Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023.
- TNX-1900 (intranasal potentiated oxytocin), in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023.
- TNX-4300 (estianeptine) is a small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease.
- A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023.